MedTrace Logo

Study of Late Boost Strategies for HIV-uninfected Participants From Protocol RV 144

NCT01435135 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 162

Last updated 2020-11-03

No results posted yet for this study

Summary

The purpose of this study is to assess safety and tolerability of late boost regimens of AIDSVAX B/E alone, ALVAC-HIV alone, or ALVAC-HIV/AIDSVAX B/E combination in HIV-uninfected participants from RV 144.

Conditions

  • HIV Infections

Interventions

BIOLOGICAL

ALVAC-HIV

1 mL per injection containing 10\^6 CCID50/dose administered

BIOLOGICAL

AIDSVAX B/E

1 mL per injection (300 ug dose/antigen for a total of 600ug/dose administered)

BIOLOGICAL

ALVAC-HIV Placebo

1 ml per injection

BIOLOGICAL

AIDSVAX B/E Placebo

1 ml per injection

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • U.S. Army Medical Research and Development Command

    lead FED

Principal Investigators

  • Supachai Rerks-Ngarm, MD · Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2021-07-31
Completion
2021-07-31

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01435135 on ClinicalTrials.gov